ABAmbros J. Beer

Ambros J. Beer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ambros J. Beer has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • PET Imaging of αvβ3 Expression in Cancer Patients

    by Ambros J. Beer, Markus Schwaiger

    Imaging of αvβ3 expression in malignant diseases has been extensively studied in the last years, mainly because the level of integrin αvβ3 expression might be a surrogate parameter of angiogenic activity. Most studies have been performed using preclinical tumor models but recently first results if imaging αvβ3 expression in patients have been published. The first approach used was the radiotracer approach with tracers for positron emission tomography (PET) like [18F]Galacto-RGD or tracers for single photon emission computed tomography (SPECT) like [99mTc]NC100692. In this article we will focus on the experimental design and methodology of PET imaging of αvβ3 expression with the tracer [18F]Galacto-RGD. Common difficulties and pitfalls in image acquisition and interpretation will be discussed. Finally, the performance of PET will be compared to other methods of imaging of αvβ3 expression, like magnetic resonance imaging, ultrasound, or optical imaging.


  • Restricted Water Diffusibility as Measured by Diffusion-weighted MR Imaging and Choline Uptake in 11C-Choline PET/CT are Correlated in Pelvic Lymph Nodes in Patients with Prostate Cancer

    by Ambros J. Beer, Matthias Eiber, Michael Souvatzoglou, Konstantin Holzapfel, Carl Ganter, Gregor Weirich, Tobias Maurer, Hubert Kübler, Hans-Juergen Wester, Jochen Gaa, et al.

    11C-Choline-positron emission tomography (PET)/computed tomography (CT) is increasingly used in patients with prostate cancer. Another promising technique for assessment of tumor biology is diffusion-weighted MR imaging (DWI). The aim of the study was to compare the functional parameters standardized uptake value (SUV) in PET and apparent diffusion coefficient (ADC) value in DWI of lymph nodes in prostate cancer patients. Fourteen patients with prostate cancer underwent DWI at 1.5T and 11C-Choline-PET/CT. ADC values and SUVs of all lymph nodes larger than 5 mm (n = 55) were compared by using linear regression analysis. Performance of DWI and 11C-Choline PET was assessed by receiver operator characteristic curve analysis using histopathology or clinical follow-up as standard of reference. ADC values and SUV showed a moderate but highly significant inverse correlation (r = −0.5144, p < 0.0001). In lymph nodes with low ADC values, the dispersion of SUV was more pronounced. Moreover, a highly significant difference was observed for mean ADC values and SUV in lymph nodes considered as benign or malignant by follow-up/histopathology (ADC 1.60 ± 0.24 vs. 1.09 ± 0.23 × 10−3 mm2/s; SUV 1.82 ± 0.57 vs. 4.68 ± 03.12; p < 0.0001, respectively). These pilot data propose the ADC value in DWI as a new potential imaging biomarker which might provide additional information on tumor pathophysiology compared to the SUV in 11C-Choline PET/CT.


  • Open Access

    Imaging of integrin αvβ3 expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography

    by Oliver Schnell, Bjarne Krebs, Janette Carlsen, Isabelle Miederer, Claudia Goetz, Roland H. Goldbrunner, Hans-JürGen Wester, Roland Haubner, Gabriele PöpPerl, Markus HoltmannspötTer, et al.

    Inhibitors targeting the integrin αvβ3 are promising new agents currently tested in clinical trials for supplemental therapy of glioblastoma multifor


  • Top Cited Papers

    Imaging of integrin αvβ3 expression

    by Ambros J. Beer, Markus Schwaiger

    The integrin αvβ3 plays an important role in angiogenesis and tumor metastasis. It is expressed on activated endothelial cells as well as some tumor cells. Therefore it is a promising imaging target as a potential surrogate parameter of angiogenic activity. Molecular imaging of αvβ3 expression could potentially facilitate response evaluation of antiangiogenic drugs (e. g. bevacizumab) or aid in selecting and monitoring patients receiving humanized monoclonal antibody therapies directed against αvβ3 (EMD121974). Therefore many different approaches for imaging of αvβ3 expression have been studied in the recent years, including positron emission tomography (PET), single photon emission tomography (SPECT), magnetic resonance imaging (MRI), optical imaging and ultrasound using targeted microbubbles. While optical imaging techniques lend themselves for preclinical studies, PET and SPECT using the αvβ3 specific tracers [18F]galacto-RGD and [99mTc]NC100692 are the only techniques up to now which have been successfully used in patients. The various advantages and disadvantages of several imaging techniques will be discussed in this article.


  • Open Access

    Patterns of αvβ3 Expression in Primary and Metastatic Human Breast Cancer as Shown by 18F-Galacto-RGD PET

    by Ambros J. Beer, Markus Niemeyer, Janette Carlsen, Mario Sarbia, Jörg Nährig, Petra Watzlowik, Hans-Jürgen Wester, Nadia Harbeck, Markus Schwaiger

    The integrin αvβ3 is a key player in angiogenesis and metastasis. Our aim was to study the uptake patterns of the αvβ3-selective PET tracer 18F-galacto-RGD in invasive ductal breast cancer. Methods: Sixteen patients with primary (n = 12) or metastasized breast cancer (n = 4) were examined with 18F-galacto-RGD PET. Standardized uptake values (SUVs) were derived by region-of-interest analysis, and immunohistochemistry of αvβ3 expression was performed (n = 5). Results: 18F-Galacto-RGD PET identified all invasive carcinomas, with SUVs from 1.4 to 8.7 (mean ± SD, 3.6 ± 1.8; tumor-to-blood and tumor-to-muscle ratios, 2.7 ± 1.6 and 6.2 ± 2.2, respectively). Lymph-node metastases were detected in 3 of 8 patients (mean SUV, 3.3 ± 0.8). SUVs in distant metastases were heterogeneous (2.9 ± 1.4). Immunohistochemistry confirmed αvβ3 expression predominantly on microvessels (5/5) and, to a lesser extent, on tumor cells (3/5). Conclusion: Our results suggest generally elevated and highly variable αvβ3 expression in human breast cancer lesions. Consequently, further imaging studies with 18F-galacto-RGD PET in breast cancer patients for assessment of angiogenesis or planning of αvβ3-targeted therapies are promising.


  • Open Access

    Comparison of Integrin αvβ3 Expression and Glucose Metabolism in Primary and Metastatic Lesions in Cancer Patients: A PET Study Using 18F-Galacto-RGD and 18F-FDG

    by Ambros J. Beer, Sylvie Lorenzen, Stephan Metz, Ken Herrmann, Petra Watzlowik, Hans-Jürgen Wester, Christian Peschel, Florian Lordick, Markus Schwaiger

    The expression of αvβ3 and glucose metabolism are upregulated in many malignant lesions, and both are known to correlate with an aggressive phenotype. We evaluated whether assessment of αvβ3 expression and of glucose metabolism with PET using 18F-galacto-RGD and 18F-FDG provides complementary information in cancer patients. Methods: Eighteen patients with primary or metastatic cancer (non–small cell lung cancer [NSCLC], n = 10; renal cell carcinoma, n = 2; rectal cancer, n = 2; others, n = 4) were examined with PET using 18F-galacto-RGD and 18F-FDG. Standardized uptake values (SUVs) were derived by volume-of-interest analysis. 18F-Galacto-RGD and 18F-FDG PET results were compared using linear regression analysis for all lesions (n = 59; NSCLC, n = 39) and for primaries (n = 14) and metastases to bone (n = 11), liver (n = 10), and other organs (n = 24) separately. Results: The sensitivity of 18F-galacto-RGD PET compared with clinical staging was 76%. SUVs for 18F-FDG ranged from 1.3 to 23.2 (mean ± SD, 7.6 ± 4.9) and were significantly higher than SUVs for 18F-galacto-RGD (range, 0.3–6.8; mean ± SD, 2.7 ± 1.5; P < 0.001). There was no significant correlation between the SUVs for 18F-FDG and 18F-galacto-RGD for all lesions (r = 0.157; P = 0.235) or for primaries, osseous or soft-tissue metastases separately (P > 0.05). For the subgroup of lesions in NSCLC, there was a weak correlation between 18F-FDG and 18F-galacto-RGD uptake (r = 0.353; P = 0.028). Conclusion: Tracer uptake of 18F-galacto-RGD and 18F-FDG does not correlate closely in malignant lesions. Whereas 18F-FDG PET is more sensitive for tumor staging, 18F-galacto-RGD PET warrants further evaluation for planning and response evaluation of targeted molecular therapies with antiangiogenic or αvβ3-targeted drugs.


  • [18F]Galacto-RGD Positron Emission Tomography for Imaging of αvβ3 Expression on the Neovasculature in Patients with Squamous Cell Carcinoma of the Head and Neck

    by Ambros J. Beer, Anca-Ligia Grosu, Janette Carlsen, Andreas Kolk, Mario Sarbia, Isabelle Stangier, Petra Watzlowik, Hans-Jürgen Wester, Roland Haubner, Markus Schwaiger

    Purpose: [18F]Galacto-RGD has been developed for positron emission tomography (PET)–imaging of αvβ3 expression, a receptor involved in angiogenesis and metastasis. Our aim was to study the feasibility of PET imaging with [18F]Galacto-RGD in patients with squamous cell carcinoma of the head and neck (SCCHN). Experimental Design: Eleven patients with primary diagnosis of SCCHN were examined. After injection of 140 to 200 MBq [18F]Galacto-RGD, static emission scans 60 min post injection from the head to the abdomen (n = 11) and dynamic scans >60 min covering the tumor region (n = 6) for kinetic modeling were acquired. Standardized uptake values (SUV) were measured in tumors, muscle and oral mucosa. Immunohistochemistry was done using an αvβ3-specific antibody (n = 7). Image fusion with magnetic resonance imaging and/or computed tomography (CT) scans (n = 8) and calculation of tumor subvolumes based on SUVs was done using the iPlan software (BrainLAB). Results: [18F]Galacto-RGD PET identified 10 of 12 tumors, with SUVs ranging from 2.2 to 5.8 (mean, 3.4 ± 1.2). Two tumors 18F]Galacto-RGD PET with magnetic resonance imaging/multislice CT and definition of tumor subvolumes was feasible in all cases. Conclusions: [18F]Galacto-RGD PET allows for specific imaging of αvβ3 expression in SCCHN with good contrast. Image fusion and definition of tumor subvolumes is feasible. This technique might be used for the assessment of angiogenesis and for planning and response evaluation of αvβ3-targeted therapies.


  • Molekulare Bildgebung mit neuen PET-Tracern

    by A. J. Beer, M. Schwaiger

    Die Positronenemissionstomographie (PET) hat in den letzten Jahren zunehmend an Bedeutung gewonnen, v. a. auf dem Gebiet der Onkologie, sowohl im Rahmen der Primärdiagnostik von Tumoren als auch bei der Beurteilung des Therapieansprechens. Dabei findet hauptsächlich das Glukoseanalogon [18F]FDG Verwendung. In diesem Artikel soll speziell auf neu entwickelte, spezifischere Tracer für die PET eingegangen werden. Diese Substanzen ermöglichen die molekulare Bildgebung biologischer Prozesse und Gewebeeigenschaften wie Proliferation und Hypoxie. Ebenso kann die Expression bestimmter Rezeptoren sichtbar gemacht werden, wie des Somatostatinrezeptors 2 oder des Integrins αvβ3. Auch die Genexpression kann mittels PET nichtinvasiv dargestellt werden. Während die meisten dieser Ansätze erst am Anfang der klinischen Evaluation stehen, könnten die Bildgebung der Proliferation und Hypoxie in naher Zukunft Eingang in die klinische Routine finden. In the recent years, positron emission tomography (PET) has gained more and more importance, especially in oncology for primary staging, as well as for response evaluation. The glucose analogon 18F-FDG is the most widely used tracer up to now. In this paper, we review the applications of newly developed, more specific PET tracers. These tracers allow for imaging of a variety of biological processes, such as hypoxia and proliferation. The expression of different receptors can be visualized, like the somatostatin receptor 2 and the integrin αvβ3. Moreover, gene expression can be imaged as well. While most of these approaches are currently in the first phases of clinical evaluation, imaging of hypoxia and proliferation might be integrated into the daily routine in the near future.


  • Top Cited Papers

    Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin αvβ3 Expression in Man

    by Ambros J. Beer, Roland Haubner, Mario Sarbia, Michael Goebel, Stephan Luderschmidt, Anca Ligia Grosu, Oliver Schnell, Markus Niemeyer, Horst Kessler, Hans-Jürgen Wester, et al.

    Purpose: The integrin αvβ3 plays a key role in angiogenesis and tumor cell metastasis and is therefore an important target for new therapeutic and diagnostic strategies. We have developed [18F]Galacto-RGD, a highly αvβ3-selective tracer for positron emission tomography (PET). Here, we show, in man, that the intensity of [18F]Galacto-RGD uptake correlates with αvβ3 expression. Experimental Design: Nineteen patients with solid tumors (musculoskeletal system, n = 10; melanoma, n = 4; head and neck cancer, n = 2; gliobastoma, n = 2; and breast cancer, n = 1) were examined with PET using [18F]Galacto-RGD before surgical removal of the tumor lesions. Snap-frozen specimens (n = 26) were collected from representative areas with low and intense standardized uptake values (SUV) of [18F]Galacto-RGD. Immunohistochemistry was done using the αvβ3-specific antibody LM609. Intensity of staining (graded on a four-point scale) and the microvessel density of αvβ3-positive vessels were determined and correlated with SUV and tumor/blood ratios (T/B). Results: Two tumors showed no tracer uptake (mean SUV, 0.5 ± 0.1). All other tumors showed tracer accumulation with SUVs ranging from 1.2 to 10.0 (mean, 3.8 ± 2.3; T/B, 3.4 ± 2.2; tumor/muscle ratio, 7.7 ± 5.4). The correlation of SUV and T/B with the intensity of immunohistochemical staining (Spearman's r = 0.92; P < 0.0001) as well as with the microvessel density (Spearman's r = 0.84; P < 0.0001) were significant. Immunohistochemistry confirmed lack of αvβ3 expression in normal tissue (benign lymph nodes, muscle) and in the two tumors without tracer uptake. Conclusions: Molecular imaging of αvβ3 expression with [18F]Galacto-RGD in humans correlates with αvβ3 expression as determined by immunohistochemistry. PET with [18F]Galacto-RGD might therefore be used as a new marker of angiogenesis and for individualized planning of therapeutic strategies with αvβ3-targeted drugs.


  • Comparison of 16-MDCT and MRI for Characterization of Kidney Lesions

    by Ambros J. Beer, Martin Dobritz, Niko Zantl, Gregor Weirich, Jens Stollfuss, Ernst J. Rummeny

    OBJECTIVE. The objective of our study was to compare the diagnostic performance of 16-MDCT with that of MRI in the characterization of kidney lesions.SUBJECTS AND METHODS. Twenty-eight patients with kidney lesions detected with sonography and requiring further evaluation were examined. MDCT was performed in the unenhanced, arterial, and portal venous phases. MRI was performed at 1.5 T with T2- and T1-weighted and dynamic gadolinium-enhanced sequences. Consensus reading was done by two radiologists. Image quality was rated on a four-point scale. Classification of lesions as surgical or nonsurgical was done with five levels of confidence, and it was required that a definite diagnosis be assigned to each lesion. The 1997 TNM classification was used for staging. Statistical analysis was done by receiver operating characteristic analysis or paired Student's t test. Histologic or follow-up findings at least 12 months after the primary diagnosis served as the standard of reference.RESULTS. The image quality of M...